ACC 2021 | LAAOS III: Appendage Closure During Central Vascular Surgery

According to the LAAOS III study, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in the New England Journal of Medicine (NEJM), patients with atrial fibrillation who undergo central vascular surgery for any other indication find benefit in appendage closure during said surgery.

ACC 2021 | LAAOS III: Cierre de orejuela durante una cirugía vascular central

Using oral anticoagulation agents, patients undergoing appendage closure had a rate of stroke and systemic embolism of 4.8% vs. 7% for patients whose appendages were left untouched. This difference is highly significant (hazard ratio [HR]: 0.67; 95% confidence interval [CI]: 0.53-0.85).

This work provides definite information about the benefits of appendage closure in terms of stroke in patients with atrial fibrillation. The benefit is even greater if the peri-operative period is excluded.

Current American and European guidelines provide a class 2B recommendation to appendage closure during surgery. These new data is bound to change this recommendation.

The LAAOS III study was conducted in 105 centers in 27 countries and was designed to provide definite information on the topic—which it ultimately did.

After randomizing 5000 patients, the safety committee recommended interrupting the study due to the clear benefit observed in the active arm.


Read also: ACC 2021 | Stress Increases Events in Young Patients with Prior MI.


All included patients had atrial fibrillation, a CHA2DS2-VASc score ≥2, and an indication for cardiac surgery.

About two thirds of patients underwent valvular surgery and 20% had isolated myocardial revascularization surgery. 

Up to 30% of patients had prior ablation resulting from their atrial fibrillation. Pump time (119 vs. 113 min) and clamp duration (86 vs. 82 min; p < 0.001) were significantly longer in the active arm, but accounted for only five extra minutes, which were worth it.


Read also: Is Rheumatic Etiology Counter Indicated for TAVR?


While all techniques for appendage surgical closure were allowed in the protocol, the most used were amputation and suture closure of the stump.

Closure significantly reduced the chance of stroke and systemic embolism at 3.8 years of follow-up, driven by a lower chance of stroke (4.2% vs. 6.6%; HR: 0.62; 95% CI: 0.48 to 0.80). The curves began to separate a few days after surgery and were completely divergent after 30 days.

cierre-orejuela-laaos

Original Title: Left atrial appendage occlusion during cardiac surgery to prevent stroke.

Reference: R.P. Whitlock et al. Presentado en el ACC 2021 y publicado simultáneamente en NEJM. DOI: 10.1056/NEJMoa2101897.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...